• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Reddy Kirthiga

    12/7/21 5:25:41 PM ET
    $THMA
    Finance
    Get the next $THMA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Reddy Kirthiga

    (Last) (First) (Middle)
    C/O PEAR THERAPEUTICS, INC.
    200 STATE STREET, 13TH FLOOR

    (Street)
    BOSTON MA 02109

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Pear Therapeutics, Inc. [ PEAR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/03/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $9.3 12/03/2021 A 70,560 (1) 12/03/2031 Class A Common Stock 70,560 $0 70,560 D
    Explanation of Responses:
    1. The option becomes exercisable for 33% shares on December 3, 2022, 33% of the shares on December 3, 2023 and 34% of the shares on December 3, 2024.
    /s/ Stacie S. Aarestad, Attorney-in-Fact 12/07/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $THMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THMA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $THMA
    SEC Filings

    View All

    SEC Form 25-NSE filed by Thimble Point Acquisition Corp.

    25-NSE - Thimble Point Acquisition Corp. (0001835567) (Subject)

    12/3/21 4:02:15 PM ET
    $THMA
    Finance

    SEC Form 425 filed by Thimble Point Acquisition Corp.

    425 - Thimble Point Acquisition Corp. (0001835567) (Subject)

    11/30/21 4:42:53 PM ET
    $THMA
    Finance

    Thimble Point Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Thimble Point Acquisition Corp. (0001835567) (Filer)

    11/30/21 4:38:59 PM ET
    $THMA
    Finance

    $THMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription Digital Therapeutics Company

    Publicly traded company called Pear Therapeutics, Inc. to begin trading on Nasdaq under ticker symbol "PEAR" starting December 6, 2021 Total expected gross proceeds from transaction totaling approximately $175 million Pear Therapeutics, Inc. ("Pear Therapeutics"), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), announced today the completion of its business combination with Thimble Point Acquisition Corp. ("Thimble Point") (NASDAQ:THMA), a special purpose acquisition company ("SPAC"). The publicly traded company will be known as Pear Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol "

    12/3/21 4:12:00 PM ET
    $THMA
    Finance

    Pear Therapeutics to Participate in Evercore ISI Fourth Annual HealthCONx Conference

    Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management will participate in the Evercore ISI Fourth Annual HealthCONx Conference on Wednesday, December 1, 2021. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 8:50 a.m. ET. A live audio webcast can be accessed by clicking here and will be made available on Pear's website at www.peartherapeutics.com. A replay will be available for approximately 30 days following the live presentation. About Pear Therapeutics Pear Therapeutics is the leader in prescription digital therapeutics, or PD

    11/23/21 8:00:00 AM ET
    $THMA
    Finance

    Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use Disorder

    Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its reSET-A™ PDT product candidate designed for the treatment of alcohol use disorder (AUD). reSET-A potentially expands Pear's addiction franchise, which includes FDA-authorized products to treat substance use disorder (SUD) and opioid use disorder (OUD). This is the second such Breakthrough Device Designation received by Pear, following the designation awarded for reSET-O®, the first ever for a PDT, which was for the treatment

    11/22/21 8:00:00 AM ET
    $THMA
    Finance

    $THMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider 5am Partners Iv, Llc claimed ownership of 18,631,771 shares

    3 - Pear Therapeutics, Inc. (0001835567) (Issuer)

    12/13/21 4:26:37 PM ET
    $THMA
    Finance

    SEC Form 4 filed by Bauerlein Alison

    4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

    12/10/21 4:47:18 PM ET
    $THMA
    Finance

    SEC Form 4 filed by Reddy Kirthiga

    4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

    12/10/21 4:46:17 PM ET
    $THMA
    Finance

    $THMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Thimble Point Acquisition Corp.

    SC 13G - Pear Therapeutics, Inc. (0001835567) (Subject)

    12/13/21 4:30:52 PM ET
    $THMA
    Finance

    SEC Form SC 13D filed by Thimble Point Acquisition Corp.

    SC 13D - Pear Therapeutics, Inc. (0001835567) (Subject)

    12/13/21 4:16:57 PM ET
    $THMA
    Finance

    SEC Form SC 13D filed by Thimble Point Acquisition Corp.

    SC 13D - Pear Therapeutics, Inc. (0001835567) (Subject)

    12/13/21 4:16:15 PM ET
    $THMA
    Finance